$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000141057823000185 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$880.0K	$597.0K	$1.683M
YoY Change	118.36%		67.46%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.983M	$9.423M	$33.35M
YoY Change	-11.26%	45.19%	-0.14%
% of Gross Profit
Research & Development	$6.861M	$9.352M	$35.51M
YoY Change	42.34%	123.41%	74.86%
% of Gross Profit
Depreciation & Amortization	$300.0K	$318.0K	$1.300M
YoY Change	200.0%	278.57%	301.23%
% of Gross Profit
Operating Expenses	$6.861M	$18.78M	$35.51M
YoY Change	42.34%	75.86%	74.86%
Operating Profit	-$12.96M		-$67.18M
YoY Change	5.52%		27.48%
Interest Expense	$1.027M	-$7.585M	$6.068M
YoY Change	-46.03%	-105.25%	21.09%
% of Operating Profit
Other Income/Expense, Net	$2.312M		-$37.85M
YoY Change	-219.92%		-116.33%
Pretax Income	-$10.65M	-$28.30M	-$105.0M
YoY Change	-25.06%	-121.23%	-158.64%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$10.70M	-$28.30M	-$105.0M
YoY Change	-24.65%	-121.23%	-158.62%
Net Earnings / Revenue	-1215.91%	-4740.03%	-6238.86%
Basic Earnings Per Share	-$0.01		-$0.10
Diluted Earnings Per Share	-$0.01	-$0.03	-$0.10
COMMON SHARES
Basic Shares Outstanding	1.073B	1.053B	1.016M
Diluted Shares Outstanding	1.075M		1.016M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.191M	$6.965M	$6.965M
YoY Change	-11.09%	-54.08%	-54.08%
Cash & Equivalents	$6.191M	$6.965M	$6.965M
Short-Term Investments
Other Short-Term Assets	$3.300M	$2.460M	$2.460M
YoY Change	43.1%	15.98%	15.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$9.491M	$9.425M	$9.425M
YoY Change	2.4%	-45.49%	-45.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.57M	$13.42M	$19.64M
YoY Change	-5.67%	-10.71%	-1.41%
Goodwill	$626.0K	$626.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$362.0K	$345.0K	$345.0K
YoY Change	3.72%	-66.7%	-66.7%
Total Long-Term Assets	$23.38M	$21.90M	$21.90M
YoY Change	9.31%	-4.25%	-4.25%
TOTAL ASSETS
Total Short-Term Assets	$9.491M	$9.425M	$9.425M
Total Long-Term Assets	$23.38M	$21.90M	$21.90M
Total Assets	$32.87M	$31.32M	$31.32M
YoY Change	7.22%	-22.0%	-22.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$20.64M	$17.64M	$17.64M
YoY Change	93.87%	61.16%	61.16%
Accrued Expenses	$369.0K	$354.0K	$354.0K
YoY Change	13.54%	11.67%	11.67%
Deferred Revenue
YoY Change
Short-Term Debt	$135.0K	$135.0K	$135.0K
YoY Change
Long-Term Debt Due	$10.47M	$15.40M	$15.40M
YoY Change	-13.58%	112.78%	112.78%
Total Short-Term Liabilities	$44.71M	$126.0M	$126.0M
YoY Change	-65.61%	-5.8%	-5.8%
LONG-TERM LIABILITIES
Long-Term Debt	$16.02M	$5.991M	$5.991M
YoY Change	-0.89%	-76.18%	-76.18%
Other Long-Term Liabilities	$4.370M	$4.370M	$4.370M
YoY Change	-12.74%	-16.38%	-16.38%
Total Long-Term Liabilities	$20.39M	$10.36M	$10.36M
YoY Change	-3.69%	-65.9%	-65.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.71M	$126.0M	$126.0M
Total Long-Term Liabilities	$20.39M	$10.36M	$10.36M
Total Liabilities	$65.10M	$136.4M	$136.4M
YoY Change	-56.94%	-16.93%	-16.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.308B	-$1.297B
YoY Change	8.41%	8.81%
Common Stock	$1.249B	$1.166B
YoY Change	15.19%	9.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$55.98M	-$128.1M	-$105.0M
YoY Change
Total Liabilities & Shareholders Equity	$32.87M	$31.32M	$31.32M
YoY Change	7.22%	-22.0%	-22.0%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$10.70M	-$28.30M	-$105.0M
YoY Change	-24.65%	-121.23%	-158.62%
Depreciation, Depletion And Amortization	$300.0K	$318.0K	$1.300M
YoY Change	200.0%	278.57%	301.23%
Cash From Operating Activities	-$11.24M	-$8.849M	-$52.78M
YoY Change	-13.33%	-21.31%	37.8%
INVESTING ACTIVITIES
Capital Expenditures	$1.333M	$2.160M	$2.902M
YoY Change	-2398.28%	-239.09%	-148.25%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.333M	-$2.160M	-$2.902M
YoY Change	2198.28%	39.09%	-51.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.58M	11.35M	41.97M
YoY Change	220.97%	-52.04%	-12.81%
NET CHANGE
Cash From Operating Activities	-11.24M	-8.849M	-52.78M
Cash From Investing Activities	-1.333M	-2.160M	-2.902M
Cash From Financing Activities	12.58M	11.35M	41.97M
Net Change In Cash	-774.0K	342.0K	-8.204M
YoY Change	-90.57%	-96.85%	-258.2%
FREE CASH FLOW
Cash From Operating Activities	-$11.24M	-$8.849M	-$52.78M
Capital Expenditures	$1.333M	$2.160M	$2.902M
Free Cash Flow	-$12.57M	-$11.01M	-$55.68M
YoY Change	-2.61%	13.58%	72.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001072379
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	nwbo	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	9478000
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	39700000
CY2022	dei	Security Exchange Name SecurityExchangeName	NONE
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1068400000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	357000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	948400000
CY2021	us-gaap	Fair Value Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#DerivativeGainLossOnDerivativeNet
CY2022	us-gaap	Fair Value Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#DerivativeGainLossOnDerivativeNet
CY2020	nwbo	Class Of Warrant Or Right Warrant Term ClassOfWarrantOrRightWarrantTerm	P2Y
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P20Y
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35737
CY2022	dei	Entity Registrant Name EntityRegistrantName	NORTHWEST BIOTHERAPEUTICS, INC.
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	Delaware
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3306718
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Bethesda
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20814
CY2022	dei	City Area Code CityAreaCode	240
CY2022	dei	Local Phone Number LocalPhoneNumber	497-9024
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	NWBO
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	630474000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1072879079
CY2022	dei	Auditor Firm AuditorFirmId	677
CY2022	dei	Auditor Name AuditorName	Cherry Bekaert LLP
CY2022	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6965000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15169000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2460000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2121000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9425000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	17290000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13418000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15027000
CY2022Q4	nwbo	Constructions In Progress Net ConstructionsInProgressNet	2028000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4189000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4889000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	135000
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1292000
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1292000
CY2022Q4	us-gaap	Goodwill Goodwill	626000
CY2021Q4	us-gaap	Goodwill Goodwill	626000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	345000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1036000
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	21898000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	26000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	213000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-128103000
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	22870000
CY2022Q4	us-gaap	Assets Assets	31323000
CY2021Q4	us-gaap	Assets Assets	40160000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10687000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6976000
CY2022Q4	nwbo	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	6955000
CY2021Q4	nwbo	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	3971000
CY2022Q4	nwbo	Convertible Notes Payable Net Current ConvertibleNotesPayableNetCurrent	135000
CY2021Q4	nwbo	Convertible Notes Payable Net Current ConvertibleNotesPayableNetCurrent	135000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	15403000
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	7104000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8668000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8232000
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	80559000
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	106784000
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2566000
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	250000
CY2022Q4	nwbo	Share Liability ShareLiability	678000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	354000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	317000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	126005000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	133769000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	5991000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	25156000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4370000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5226000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10361000
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	30382000
CY2022Q4	us-gaap	Liabilities Liabilities	136366000
CY2021Q4	us-gaap	Liabilities Liabilities	164151000
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	23060000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1200000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1068400000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	948400000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1068000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	948000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1164885000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1066873000
CY2022Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	79000
CY2021Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	79000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1297122000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-123991000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31323000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40160000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1683000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1192090000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3145000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1005000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1291000
CY2022	us-gaap	Revenues Revenues	1683000
CY2021	us-gaap	Revenues Revenues	1005000
CY2020	us-gaap	Revenues Revenues	1291000
CY2020	nwbo	Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series A Convertible Preferred Stock AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesAConvertiblePreferredStock	44000
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	2902000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35511000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20308000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33637000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33353000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33399000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54259000
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	68864000
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	53707000
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	87896000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-67181000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-52702000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-86605000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-25821000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	239347000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-435351000
CY2022	nwbo	Fair Value Adjustment Of Share Liability FairValueAdjustmentOfShareLiability	33000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2691000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-165000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1582000
CY2022	us-gaap	Interest Expense InterestExpense	6068000
CY2021	us-gaap	Interest Expense InterestExpense	5011000
CY2020	us-gaap	Interest Expense InterestExpense	8544000
CY2021	nwbo	Inducement Expense InducementExpense	647000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-3304000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-1696000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	2261000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37851000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	231828000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-443216000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105032000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	179126000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-529821000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-2788000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1505000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1984000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102244000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	180631000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-531805000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1015852
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	873517
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	725129
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1015852
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1133000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1007869
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	725129
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-45055000
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	6015000
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16491000
CY2020	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	19649000
CY2020	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	13915000
CY2020	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	22701000
CY2020	nwbo	Noncash Interest Expense NoncashInterestExpense	4270000
CY2020	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	6610000
CY2022	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	45048000
CY2021	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-220150000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52209000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-529821000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1984000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-362948000
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4070000
CY2021	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	7500000
CY2021	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	19975000
CY2021	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	68692000
CY2021	nwbo	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	2369000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15571000
CY2021	nwbo	Adjustment To Additional Paid In Capital Reclassification Of Warrant Liabilities Based On Authorized Shares AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares	59851000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	179126000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1505000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-123991000
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9689000
CY2022	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	11105000
CY2022	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	24434000
CY2022	nwbo	Adjustment To Additional Paid In Capital Reclassification Of Warrant Liabilities Based On Authorized Shares AdjustmentToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares	-26800000
CY2022	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	13806000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12298000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105032000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2788000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-128103000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105032000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	179126000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-529821000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1252000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	324000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	87000
CY2022	nwbo	Amortization Of Debt Discount AmortizationOfDebtDiscount	2771000
CY2021	nwbo	Amortization Of Debt Discount AmortizationOfDebtDiscount	2301000
CY2020	nwbo	Amortization Of Debt Discount AmortizationOfDebtDiscount	3013000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-25821000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	239347000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-435351000
CY2020	nwbo	Change In Fair Value Of Contingent Liability ChangeInFairValueOfContingentLiability	-913000
CY2022	nwbo	Fair Value Adjustment Of Share Liability FairValueAdjustmentOfShareLiability	33000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2691000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-165000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1582000
CY2021	nwbo	Inducement Expense InducementExpense	647000
CY2022	nwbo	Operating Lease Roa OperatingLeaseRoa	248000
CY2021	nwbo	Operating Lease Roa OperatingLeaseRoa	262000
CY2020	nwbo	Operating Lease Roa OperatingLeaseRoa	338000
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	12298000
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	15498000
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	52209000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1532000
CY2021	nwbo	Capital Expenditures Included In Accounts Payable CapitalExpendituresIncludedInAccountsPayable	33000
CY2020	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	497763000
CY2022	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	397000
CY2020	nwbo	Capital Expenditures Included In Accounts Payable CapitalExpendituresIncludedInAccountsPayable	1088000
CY2021	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-3475000
CY2020	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	2350000
CY2022	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-625000
CY2021	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	179000
CY2020	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	31000
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3492000
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	77000
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1702000
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	3354000
CY2021	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-674000
CY2020	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	431000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52775000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32093000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38299000
CY2022	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived	11541000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2902000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6015000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8142000
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	18669000
CY2022	nwbo	Proceeds From Issuance Of Redeemable Convertible Preferred Stock By Common Stock Warrant Exercise Net Of Debt Redemption ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockByCommonStockWarrantExerciseNetOfDebtRedemption	52000
CY2022	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	9465000
CY2021	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	4070000
CY2020	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	26814000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11105000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	19975000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13915000
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5600000
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	29665000
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	8557000
CY2020	nwbo	Proceeds From Warrant Modification ProceedsFromWarrantModification	4000
CY2020	nwbo	Proceeds From Issuance Of Convertible Notes Payable ProceedsFromIssuanceOfConvertibleNotesPayable	5115000
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	315000
CY2022	nwbo	Payments To Investors PaymentsToInvestors	-2566000
CY2021	nwbo	Payments To Investors PaymentsToInvestors	-250000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5489000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5828000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1556000
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	379000
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	89000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41968000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48132000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52696000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5505000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1368000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2850000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8204000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5186000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9611000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15169000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9983000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	372000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6965000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15169000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9983000
CY2020	nwbo	Issuance Of Common Stock For Unpaid Consideration Related To Acquisition IssuanceOfCommonStockForUnpaidConsiderationRelatedToAcquisition	220000
CY2022	nwbo	Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise	34000
CY2021	nwbo	Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise	20000
CY2020	nwbo	Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise	7000
CY2022	nwbo	Reclassification Of Warrant Liabilities Related To Warrants Exercised For Cash ReclassificationOfWarrantLiabilitiesRelatedToWarrantsExercisedForCash	24969000
CY2021	nwbo	Reclassification Of Warrant Liabilities Related To Warrants Exercised For Cash ReclassificationOfWarrantLiabilitiesRelatedToWarrantsExercisedForCash	68692000
CY2020	nwbo	Reclassification Of Warrant Liabilities Related To Warrants Exercised For Cash ReclassificationOfWarrantLiabilitiesRelatedToWarrantsExercisedForCash	22701000
CY2022	nwbo	Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised	26800000
CY2021	nwbo	Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised	2369000
CY2020	nwbo	Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised	9478000
CY2021	nwbo	Reclassification Of Warrant Liabilities Based On Authorized Shares ReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares	59851000
CY2020	nwbo	Reclassification Of Warrant Liabilities Based On Authorized Shares ReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares	78292000
CY2021	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived	7487000
CY2020	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived	8230000
CY2020	nwbo	Offering Cost Related To Warrant Liability OfferingCostRelatedToWarrantLiability	4876000
CY2022	nwbo	Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption IssuanceOfConvertiblePreferredStockInLieuOfDebtRedemption	3408000
CY2022	nwbo	Exercise Common Stock Warrants By Debt Redemption ExerciseCommonStockWarrantsByDebtRedemption	277000
CY2022	nwbo	Reclassification Between Shares Payable And Equity ReclassificationBetweenSharesPayableAndEquity	250000
CY2022	nwbo	Capital Expenditures Included In Accounts Payable CapitalExpendituresIncludedInAccountsPayable	699000
CY2021	nwbo	Capital Expenditures Included In Accounts Payable And Accrued Expenses To Related Parties And Affiliates CapitalExpendituresIncludedInAccountsPayableAndAccruedExpensesToRelatedPartiesAndAffiliates	370000
CY2021	nwbo	Issuance Of Common Shares To Settle Accrued Service Liability IssuanceOfCommonSharesToSettleAccruedServiceLiability	73000
CY2020	nwbo	Warrants Issued Associated With Convertible Notes Payable WarrantsIssuedAssociatedWithConvertibleNotesPayable	153000
CY2020	nwbo	Warrants Issued In Connection With Debt Modification WarrantsIssuedInConnectionWithDebtModification	395000
CY2020	nwbo	Warrant Modification In Connection With Debt Amendment WarrantModificationInConnectionWithDebtAmendment	91000
CY2020	nwbo	Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series A Convertible Preferred Stock AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesAConvertiblePreferredStock	44000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105000000.0
CY2022	us-gaap	Payments For Operating Activities PaymentsForOperatingActivities	52800000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.</p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal depository insurance coverage (“FDIC”) of $250,000. As of December 31, 2022, of the total $7.0 million in cash and cash equivalents, $0.4 million was held by foreign subsidiaries. As of December 31, 2021, of the total $15.2 million in cash and cash equivalents, $0.5 million was held by foreign subsidiaries. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	7000000.0
CY2022Q4	nwbo	Cash And Cash Equivalents Held By Foreign Subsidiaries CashAndCashEquivalentsHeldByForeignSubsidiaries	400000
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	15200000
CY2021Q4	nwbo	Cash And Cash Equivalents Held By Foreign Subsidiaries CashAndCashEquivalentsHeldByForeignSubsidiaries	500000
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2022	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Embedded Conversion Features</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates embedded conversion features within convertible debt instruments to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company records a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.</p>
CY2022	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.</p>
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	80559000
CY2022Q4	nwbo	Embedded Derivative Redemption Option Fair Value Of Embedded Derivative Liability EmbeddedDerivativeRedemptionOptionFairValueOfEmbeddedDerivativeLiability	807000
CY2022Q4	nwbo	Contingent Payable Derivative Liability ContingentPayableDerivativeLiability	8668000
CY2022Q4	nwbo	Share Liability ShareLiability	678000
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	90712000
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	106784000
CY2021Q4	nwbo	Embedded Derivative Redemption Option Fair Value Of Embedded Derivative Liability EmbeddedDerivativeRedemptionOptionFairValueOfEmbeddedDerivativeLiability	988000
CY2021Q4	nwbo	Contingent Payable Derivative Liability ContingentPayableDerivativeLiability	8232000
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	116004000
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	365754000
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	1785000
CY2021	nwbo	Bifurcated Embedded Derivative Fair Value Of Embedded Derivative Liability1 BifurcatedEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability1	947000
CY2021	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash	11210000
CY2021	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Debt Conversion FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToDebtConversion	-1925000
CY2021	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-239347000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	116004000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	191000
CY2022	nwbo	Fair Value Of Additional Share Liability FairValueOfAdditionalShareLiability	711000
CY2022	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Redemption FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtRedemption	213000
CY2022	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash	51769000
CY2022	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	25788000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	90712000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12298000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15571000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51955000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.65
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.92
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.26
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y10M24D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.97
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.98
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.033
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.01
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1600000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.24
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	104659000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.34
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	4250000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.22
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	308840000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M24D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	208525000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.37
CY2020	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P10Y
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	94000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	372219000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	910000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.92
CY2021	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P8Y7M6D
CY2021	nwbo	Stock Issued During Period Shares Stock Options Cash Exercised StockIssuedDuringPeriodSharesStockOptionsCashExercised	183000
CY2021	nwbo	Sharebasedcompensationarrangementsbysharebasedpaymentawardoptions Cash Exercises In Period Weighted Average Exercise Price SharebasedcompensationarrangementsbysharebasedpaymentawardoptionsCashExercisesInPeriodWeightedAverageExercisePrice	0.25
CY2021	us-gaap	Interest Expense InterestExpense	5011000
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4720000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.25
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	304847000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	114803000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8005000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.65
CY2022	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P4Y4M24D
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8187000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.27
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	3402000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.88
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	301263000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.34
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	135225000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	282271000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.33
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	127951000
CY2020Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
CY2022	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Period Of Notice For Exercising Any Option ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfNoticeForExercisingAnyOption	P61D
CY2020Q2	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Number Of Stock Options Agreed Not To Be Exercised By Holder ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfStockOptionsAgreedNotToBeExercisedByHolder	39200000
CY2020Q2	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Period During Which Stock Options Agreed Not To Be Exercised By Holder ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodDuringWhichStockOptionsAgreedNotToBeExercisedByHolder	P6M
CY2020Q2	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Stock Option Extended Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionExtendedContractualTerm	P6M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	78000000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1750000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000000.0
CY2020Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.22
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	300000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	13500000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13418000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15027000
CY2022	us-gaap	Depreciation Depreciation	1300000
CY2021	us-gaap	Depreciation Depreciation	300000
CY2020	us-gaap	Depreciation Depreciation	87000
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	22454000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1732000
CY2022Q4	nwbo	Fair Value Of Embedded Conversion Option FairValueOfEmbeddedConversionOption	807000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	21529000
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	35243000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	3836000
CY2021Q4	nwbo	Fair Value Of Embedded Conversion Option FairValueOfEmbeddedConversionOption	988000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	32395000
CY2021Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0100
CY2021Q4	nwbo	Debt Instrument Original Issue Discount Amount DebtInstrumentOriginalIssueDiscountAmount	1500000
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	5600000
CY2021	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	5100000
CY2021	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	800000
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	7500000
CY2021	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	1900000
CY2021	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	5800000
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	407000
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	223000
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	10000
CY2022	us-gaap	Interest Expense InterestExpense	6068000
CY2020	us-gaap	Interest Expense InterestExpense	8544000
CY2020	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.29
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	22454000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-105032000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	179126000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-529821000
CY2021	nwbo	Reversal Of Gain Due To Change In Fair Value Of Warrant Liability ReversalOfGainDueToChangeInFairValueOfWarrantLiability	-239347000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-105032000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-60221000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-529821000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1015852
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	873517
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	725129
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	76
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1015852
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1007869
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	725129
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	477773000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	396039000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	643210000
CY2022	nwbo	Amount Recognized And Expensed Related To Current Cash Component AmountRecognizedAndExpensedRelatedToCurrentCashComponent	3000000.0
CY2022	nwbo	Milestones Costs In Shares MilestonesCostsInShares	7500000
CY2022Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	5900000
CY2022	nwbo	Number Of Milestones Completed NumberOfMilestonesCompleted	7
CY2022	nwbo	Amount Recognized And Expensed Related To Cash Component AmountRecognizedAndExpensedRelatedToCashComponent	3700000
CY2022	nwbo	Amount Recognized And Expensed Related To Stock Component AmountRecognizedAndExpensedRelatedToStockComponent	3600000
CY2022	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	28584000
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	7417000
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	7543000
CY2022	us-gaap	Sublease Income SubleaseIncome	145000
CY2020	nwbo	Number Of Warrants Warrants Cashless Exercise NumberOfWarrantsWarrantsCashlessExercise	8631
CY2020	nwbo	Weighted Average Exercise Price Warrants Cashless Exercise WeightedAverageExercisePriceWarrantsCashlessExercise	0.22
CY2020	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	63010
CY2018Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	65000
CY2018Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1400000
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.24
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	329000
CY2022Q3	nwbo	Term By Which Preferred Shares Cannot Be Converted Into Common Stock TermByWhichPreferredSharesCannotBeConvertedIntoCommonStock	P3M
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1400000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11100000
CY2022	nwbo	Stock Issued During Period Shares Warrant Exercises StockIssuedDuringPeriodSharesWarrantExercises	45300000
CY2022	nwbo	Debt Instrument Redemption Shares Issued DebtInstrumentRedemptionSharesIssued	18100000
CY2022	nwbo	Debt Instrument Redemption Amount DebtInstrumentRedemptionAmount	11300000
CY2022	nwbo	Debt Instrument Redemption Amount Interest DebtInstrumentRedemptionAmountInterest	1800000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	20000000.0
CY2021	nwbo	Stock Issued During Period Shares Warrant Exercises StockIssuedDuringPeriodSharesWarrantExercises	86900000
CY2021	nwbo	Debt Instrument Percentage Of Aggregate Principal Amount For Next Offering DebtInstrumentPercentageOfAggregatePrincipalAmountForNextOffering	0.50
CY2021	nwbo	Debt Instrument Discount Rate DebtInstrumentDiscountRate	0.12
CY2021	nwbo	Inducement Expense InducementExpense	600000
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	8500000
CY2020Q4	nwbo	Class Of Warrant Or Right Agreed To Be Suspended ClassOfWarrantOrRightAgreedToBeSuspended	14600000
CY2020Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5300000
CY2021Q1	nwbo	Class Of Warrant Or Right Agreed To Be Suspended ClassOfWarrantOrRightAgreedToBeSuspended	3500000
CY2021Q1	nwbo	Class Of Warrant Or Right Agreed To Be Suspended ClassOfWarrantOrRightAgreedToBeSuspended	3500000
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	261000
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.00
CY2021Q4	nwbo	Class Of Warrant Or Right Exercise Period Of Warrants Or Rights ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights	P12M
CY2020Q4	nwbo	Shares Issued During Period Shares Upon Exercise Of Warrants SharesIssuedDuringPeriodSharesUponExerciseOfWarrants	47500000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13900000
CY2020	nwbo	Number Of Common Stock Issued Cashless Exercise NumberOfCommonStockIssuedCashlessExercise	7100000
CY2020	nwbo	Weighted Average Exercise Price Warrants Cashless Exercise WeightedAverageExercisePriceWarrantsCashlessExercise	0.22
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	359473
CY2019Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.27
CY2019	nwbo	Class Of Warrant Or Right Outstanding Remaining Contractual Term ClassOfWarrantOrRightOutstandingRemainingContractualTerm	P1Y5M1D
CY2020	nwbo	Classofwarrantorrightgranted Classofwarrantorrightgranted	88658
CY2020	nwbo	Classofwarrantorrightgrantedweightedaverageexerciseprice Classofwarrantorrightgrantedweightedaverageexerciseprice	0.22
CY2020	nwbo	Classofwarrantcontingentlyissuablewarrants Classofwarrantcontingentlyissuablewarrants	-2774
CY2020	nwbo	Classofwarrantorrightgrantedweightedaveragecontingentlyissuablewarrants Classofwarrantorrightgrantedweightedaveragecontingentlyissuablewarrants	1.48
CY2020	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	47511
CY2020	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	0.32
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	331753
CY2020Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.28
CY2020	nwbo	Class Of Warrant Or Right Outstanding Remaining Contractual Term ClassOfWarrantOrRightOutstandingRemainingContractualTerm	P1Y7M9D
CY2021	nwbo	Classofwarrantorrightgranted Classofwarrantorrightgranted	-1209
CY2021	nwbo	Classofwarrantorrightgrantedweightedaverageexerciseprice Classofwarrantorrightgrantedweightedaverageexerciseprice	1.39
CY2021	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	86726
CY2021	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.23
CY2021	nwbo	Number Of Warrants Warrants Cashless Exercise NumberOfWarrantsWarrantsCashlessExercise	19743
CY2021	nwbo	Weighted Average Exercise Price Warrants Cashless Exercise WeightedAverageExercisePriceWarrantsCashlessExercise	0.22
CY2021	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1024
CY2021	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	2.95
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	225469
CY2021Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.30
CY2021	nwbo	Class Of Warrant Or Right Outstanding Remaining Contractual Term ClassOfWarrantOrRightOutstandingRemainingContractualTerm	P0Y11M15D
CY2022	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	46671
CY2022	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.25
CY2022	nwbo	Number Of Warrants Warrants Cashless Exercise NumberOfWarrantsWarrantsCashlessExercise	35951
CY2022	nwbo	Weighted Average Exercise Price Warrants Cashless Exercise WeightedAverageExercisePriceWarrantsCashlessExercise	0.23
CY2022	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1799
CY2022	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	1.58
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	141048
CY2022Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.31
CY2022	nwbo	Class Of Warrant Or Right Outstanding Remaining Contractual Term ClassOfWarrantOrRightOutstandingRemainingContractualTerm	P1Y5M15D
CY2022Q4	nwbo	Class Of Warrant Or Right Suspended ClassOfWarrantOrRightSuspended	137000000
CY2022Q4	nwbo	Increase In Common Stock Shares Authorized IncreaseInCommonStockSharesAuthorized	500000000
CY2022Q4	us-gaap	Lease Practical Expedient Lessor Single Lease Component LeasePracticalExpedientLessorSingleLeaseComponent	true
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4700000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4200000
CY2022	nwbo	Office Space Taken Under Lease Agreement OfficeSpaceTakenUnderLeaseAgreement	The Company subleased approximately 14,459 square feet of 88,000 square foot building interior space, plus corresponding exterior support space and parking located in Sawston, UK. Lease payments under the Agreement are two times the £5.75 (approximate $6.96 per square foot based on exchange rate as of December 31, 2022) rate per square foot payable under the head lease, subject to a cap of $10 per square foot. Accordingly, the lease payments under the Sublease are set at $145,000 per year. The total lease payments paid by the Company for the overall building, exterior space and parking under the head lease are 500,000 pounds per year
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	848000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	79000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	13000
CY2022	us-gaap	Sublease Income SubleaseIncome	145000
CY2022	us-gaap	Lease Cost LeaseCost	795000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	909000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	930000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	51000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	53000
CY2021	us-gaap	Lease Cost LeaseCost	1034000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	866000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	940000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	44000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	65000
CY2020	us-gaap	Lease Cost LeaseCost	1049000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	993000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	903000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	809000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	604000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	604000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	604000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6631000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10155000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5431000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4724000
CY2022	nwbo	Original Term Of Agreement OriginalTermOfAgreement	P8M
CY2022Q3	nwbo	Litigation Settlement Waiver Of Penalty LitigationSettlementWaiverOfPenalty	135000
CY2022Q3	nwbo	Litigation Settlement Waiver Of Penalty LitigationSettlementWaiverOfPenalty	141000
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	377000
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	403000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	202525000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	193605000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17989000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17982000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	9144000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	18021000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	23637000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	247679000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	235224000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	247679000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	235224000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	709900000
CY2022Q4	nwbo	Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development DeferredTaxAssetsTaxCreditCarryForwardUnusedResearchAndDevelopment	527400000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	18000000.0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.046
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.052
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.280
CY2022	nwbo	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses	0.026
CY2021	nwbo	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses	-0.039
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.060
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.117
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.046
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8868000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5765000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3097000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1975000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-489000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-599000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-12454000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-8339000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022Q4	nwbo	Cash Deposit CashDeposit	2600000

Files In Submission

Name	View Source	Status
nwbo-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001410578-23-000185-index-headers.html	Edgar Link	pending
0001410578-23-000185-index.html	Edgar Link	pending
0001410578-23-000185.txt	Edgar Link	pending
0001410578-23-000185-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nwbo-20221231.xsd	Edgar Link	pending
nwbo-20221231x10k.htm	Edgar Link	pending
nwbo-20221231x10k001.jpg	Edgar Link	pending
nwbo-20221231xex10d88.htm	Edgar Link	pending
nwbo-20221231xex23d1.htm	Edgar Link	pending
nwbo-20221231xex31d1.htm	Edgar Link	pending
nwbo-20221231xex32d1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
nwbo-20221231_cal.xml	Edgar Link	unprocessable
nwbo-20221231_lab.xml	Edgar Link	unprocessable
nwbo-20221231_pre.xml	Edgar Link	unprocessable
nwbo-20221231x10k_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2023 Q1 Form 10-K Financial Statement

#000141057823000185 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2023 Q1 Form 10-K Financial Statement

#000141057823000185 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo